Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 60.13M P/E - EPS this Y - Ern Qtrly Grth -
Income -20.18M Forward P/E -2.24 EPS next Y - 50D Avg Chg -2.00%
Sales 1M PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -47.00%
Recommedations 2.00 Quick Ratio 6.57 Shares Outstanding 2.43M 52W Low Chg 17.00%
Insider Own 38.82% ROA -41.48% Shares Float 883.71K Beta 0.64
Inst Own 14.32% ROE -362.13% Shares Shorted/Prior 30.96K/38.06K Price 0.74
Gross Margin - Profit Margin - Avg. Volume 144,616 Target Price -
Oper. Margin -2,285.70% Earnings Date Nov 7 Volume 454,526 Change 1.10%
About vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.

VTVT Chatroom

User Image GDS_investing Posted - 30 minutes ago

@Stocksrockman $vtvt That's how I see it

User Image GDS_investing Posted - 36 minutes ago

@Stocksrockman $VTVT float only 640K

User Image Stocksrockman Posted - 1 day ago

$ZONE slaps are coming in right now. This is poised for a run $FLYE up 13% with $icu $IONQ is bullish again and so is $VTVT

User Image EpiCRise98 Posted - 1 day ago

$VTVT not bad

User Image LongBallBarn Posted - 1 day ago

$PULM $TCBP $VTVT

User Image terrapin22 Posted - 1 day ago

$VTVT can fly

User Image JimJames Posted - 1 day ago

$VTVT

User Image Bullfinch2 Posted - 2 days ago

$VTVT premarket -13%? Any news?

User Image LongBallBarn Posted - 2 days ago

$CKPT $TENX $VTVT

User Image Bullfinch2 Posted - 2 days ago

$VTVT gradually moving upwards. Nice

User Image dcajic2 Posted - 3 days ago

$VTVT how did they make progress addressing the basis for the clinical hold. It sounds like they don’t understand how they can fix it. There is so little chance that fda will ever lift the clinical hold. It has been apparent for some time that this company has been failing to understand that they in real trouble

User Image GDS_investing Posted - 3 days ago

$VTVT in the move long and strong "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of hypoglycemia in patients with type 1 diabetes. During the quarter, our team made progress addressing the basis for the clinical hold placed on our clinical program by the Food and Drug Administration in July,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. "We look forward to continuing our discussion with the FDA regarding the clinical hold and our clinical program for cadisegliatin."

User Image prismmarketview Posted - 3 days ago

$VTVT continuing to be able to hold $13

User Image Estimize Posted - 4 days ago

$VTVT reported -0.88 EPS and - revenue for Q3. http://www.estimize.com/intro/vtvt?chart=historical&metric_name=eps&utm_content=VTVT&utm_med

User Image dcajic2 Posted - 4 days ago

$VTVT We look forward to continuing our discussions. What do they not tell people what they have to do to be able to get clinical hold lifted. What it sounds like is they are no closer to having clinical hold lifted than they did 3 months ago. Just pathetic. At this rate they will run let of money. Executives still getting paid for doing what

User Image dcajic2 Posted - 4 days ago

$VTVT What pure lies!!!!! Our cadisegliatin continues to show promise!! There has been a clinical hold for over 3 months

User Image dcajic2 Posted - 4 days ago

$VTVT Stop repeating the same lies. There are million of shares not 640k. Just do the math

User Image JohnWick0 Posted - 4 days ago

$VTVT "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of hypoglycemia in patients with type 1 diabetes. During the quarter, our team made progress addressing the basis for the clinical hold placed on our clinical program by the Food and Drug Administration in July,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. "We look forward to continuing our discussion with the FDA regarding the clinical hold and our clinical program for cadisegliatin."

User Image Bullfinch2 Posted - 4 days ago

$VTVT what time will q3 be released?

User Image JimJames Posted - 4 days ago

$VTVT soon!

User Image GDS_investing Posted - 4 days ago

$VTVT hug reversal here very low float only 640k volume is the key , a lot of room to run long and strong $VTVT

User Image dcajic2 Posted - 4 days ago

$VTVT Where is the sec

User Image UncleStock Posted - 5 days ago

$ORMP $ALT $VTVT suggested for #GLP-1 - value screen: https://zpr.io/G7kCSzs5srLj

User Image dcajic2 Posted - 5 days ago

$VTVT Love it. We need huge volume for a run up. Today volume was good and stock is down. Why is the stock down because so very likely that clinical hold will ever be lifted and that means zero chance of FDA approval

User Image dcajic2 Posted - 5 days ago

$VTVT Good news any day??? Seriously. Working diligently with the agency is what was said over 3 months and not one word from the company.

User Image dcajic2 Posted - 5 days ago

$VTVT Seriously some people still blatantly lie. Float is over 2 million not 640k so stop the lying. Just go do the math

User Image GDS_investing Posted - 5 days ago

$VTVT good news any day .... "“We are working diligently with the agency to resolve the clinical hold and resume enrollment as quickly as possible,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics." float only 640k we need volume for huge runup LONG and STRONG $VTVT

User Image UncleStock Posted - 1 week ago

$ORMP $ALT $VTVT suggested for #GLP-1 - value screen: https://zpr.io/G7kCSzs5srLj

User Image GDS_investing Posted - 1 week ago

The markets are exploding And these are still under water $vtvt $sskn $toon $rfl all long Their day will come

User Image dcajic2 Posted - 1 week ago

$VTVT Q3 results can’t be positive since they make no real money and still they have a clinical hold. Clinical hold was supposed to be simple yet it has been 3 months without one word from this comoany. Obviously not easy which creates a huge problem for this company

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
FRY JOHN A Director Director Nov 28 Buy 0.83 61,000 50,630 61,000 11/30/22